Biolab Farmacêutica and Mitelos agree to market OTIBLOCK® spray in Brazil

OTIBLOCK® spray represents a therapeutic alternative to treat impacted earwax.

OTIBLOCK® spray removes impacted earwax from the ear canal thanks to its formulation, which is oil-free and helps the ear to maintain its physiological pH. OTIBLOCK® which is due to go on sale by Biolab in the mentioned market has been developed by Mitelos.

By means of this agreement, Biolab will add yet another product to its ENT portfolio, a specialty in which it has significant commercial activity.

Caring for the ears is essential to prevent hearing problems and other symptoms. It is estimated that 1 in 20 adults at some point in their life will experience impacted ear wax. This figure rises to 1 in 3 people in the elderly population. 

In addition to treat impacted earwax, OTIBLOCK® benefits patients prone to recurrencies like those with narrow external ear canals, users of headphones and hearing aids, etc.

The product is already marketed in several countries worldwide with a very good acceptance by Doctors and patients.

OTIBLOCK® comes in a 45-mL dosage form, including an ergonomic, push-button otic spray, which enables the correct and convenient self-administration by the patient.